Publications
- Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Erlotinib in the treatment of advanced non-small cell lung cancer - present experience and results in the Czech Repuiblic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Current position of afatinib in the therapy of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Tagrisso (osimertinib)2016 | Publication without faculty affiliation
- Biological treatment of lung cancer +12015 | Publication without faculty affiliation
- Current therapeutic options for advanced/metastatic non-small cell lung cancer2011 | Publication without faculty affiliation
- Role of histology in the choice of treatment for advanced non-small-cell lung cancer2010 | Publication without faculty affiliation
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...
